Ria Goswami

Dr. Ria Goswami

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Cell
Verified
Journal Article
Closed access
DMDavid R. Martinez
David R. Martinez
YFYouyi Fong
Youyi Fong
SLShuk Hang Li
Shuk Hang Li
FYFang Yang
Fang Yang
MJMadeleine F. Jennewein
Madeleine F. Jennewein
SPSallie Permar
Sallie Permar

1 December 2012 in Antiviral Research
Verified
Journal Article
Closed access
RGRia Goswami
Ria Goswami
SGS. Gershburg
S. Gershburg
ASA. Satorius
A. Satorius
EGEdward Gershburg
Edward Gershburg

10 November 2021 in iScience
Verified
Journal Article
Open access
RGRia Goswami
Ria Goswami
VRVeronica S. Russell
Veronica S. Russell
JTJoshua J. Tu
Joshua J. Tu
CTCharlene Thomas
Charlene Thomas
PHPhilip Hughes
Philip Hughes
SPSallie Permar
Sallie Permar
Currently available SARS-CoV-2 therapeutics are targeted toward moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. Although vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways previously associated with poor SARS-CoV-2 disease outcomes. In addition, SNX-5422 interrupted expression of host factors demonstrated to be crucial for SARS-CoV-2 replication. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations.

28 April 2020 in mBio
Verified
Journal Article
Open access
PDF file
DMDavid R. Martinez
David R. Martinez
JTJoshua J. Tu
Joshua J. Tu
AKAmit Kumar
Amit Kumar
JMJesse Francis Mangold
Jesse Francis Mangold
RMRiley J. Mangan
Riley J. Mangan
SPSallie Permar
Sallie Permar
Efforts to eliminate MTCT of HIV with antiretroviral therapy (ART) have met little success, with >180,000 infant infections each year worldwide. It is therefore likely that additional immunologic strategies that can synergize with ART will be required to eliminate MTCT of HIV. To this end, understanding the role of maternal HIV Env-specific IgG antibodies in the setting of MTCT is crucial. In this study, we found that maternal-plasma broadly neutralizing antibody (bNAb) responses can select for T/F viruses that initiate infection in infants. We propose that clinical trials testing the efficacy of single bNAb specificities should not include HIV-infected pregnant women, as a single bNAb might select for neutralization-resistant infant-T/F viruses.

29 October 2019 in mBio
Verified
Journal Article
Open access
PDF file
RGRia Goswami
Ria Goswami
ANAshley N. Nelson
Ashley N. Nelson
JTJoshua J. Tu
Joshua J. Tu
MDMaria Dennis
Maria Dennis
LFLiqi Feng
Liqi Feng
SPSallie Permar
Sallie Permar
Novel interventions that do not rely on daily adherence to ART are needed to achieve sustained viral remission for perinatally infected children, who currently rely on lifelong ART. Considering the risks and expense associated with ART interruption trials, the identification of biomarkers of viral rebound will prioritize promising therapeutic intervention strategies, including anti-HIV Env protein therapeutics. However, comprehensive studies to identify those biomarkers are logistically challenging in human infants, demanding the need for relevant nonhuman primate models of HIV rebound. In this study, we developed an infant RM model of oral infection with simian-human immunodeficiency virus expressing clade C HIV Env and short-term ART followed by ATI, longitudinally characterizing the immune responses to viral infection during ART and after ATI. Additionally, we compared this infant RM model to an analogous adult RM rebound model and identified virologic and immunologic correlates of the time to viral rebound after ATI.

1 June 2020 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
SBStella J. Berendam
Stella J. Berendam
ANAshley N. Nelson
Ashley N. Nelson
RGRia Goswami
Ria Goswami
DPDeborah Persaud
Deborah Persaud
NHNancy L. Haigwood
Nancy L. Haigwood
SPSallie Permar
Sallie Permar